Adalimumab Dose Escalation Is Effective And Well Tolerated In Crohn'S Disease Patients With Secondary Loss Of Response To Adalimumab
Digestive and Liver Disease(2016)
摘要
Abstract Background Although adalimumab is effective in Crohn’s disease, most patients experience a loss of response over time. The aim of the present study was to evaluate efficacy and safety of adalimumab dose escalation and identify predictors of a clinical response in Crohn’s disease patients with a secondary loss of response. Methods We performed a retrospective and observational study including all Crohn’s disease patients who underwent dose escalation of adalimumab after a secondary loss of response from 2007 to 2015. Results A clinical response was observed in 99/124 (79%) patients at 3 months and in 62/107 (61%) patients at 12 months. The predictive factors of response to ADA dose escalation at 12 months on multivariate analysis were: maintenance therapy of 40 mg every week rather than 80 mg every other week (OR 3.64, 95% CI: 1.28–10.37) and a CRP level ≤ 5 mg/L at adalimumab dose escalation (OR 6.64, 95% CI: 1.40–27.53). Adalimumab was withdrawn in 4 patients due to side effects. Conclusions Adalimumab dose escalation is an effective and well-tolerated therapeutic option in patients with secondary loss of response. A 40 mg every week optimized regimen was predictive of a response to ADA dose escalation.
更多查看译文
关键词
Anti-TNF,Optimization,Therapeutic strategy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要